Oct 5 Drugmaker Insmed Inc said it on
Wednesday it had bought the rights to an experimental
early-stage respiratory drug from Britain's AstraZeneca Plc
in a deal worth $150 million.
AstraZeneca will get $30 million in upfront fees and $120
million in various milestone payments, Insmed said.
The deal adds AstraZeneca's AZD7986 compound to Insmed's
pipeline. AZD7986 is designed to stop an enzyme that regulates
inflammation in the respiratory system.
Insmed, which focuses on developing treatments for
respiratory diseases, said it would start a mid-stage study of
the drug in non-cystic fibrosis bronchiectasis, a disease in
which the airways in the lungs become permanently dilated due to
chronic inflammation and infection.
(Reporting by Vidya L Nathan in Bengaluru; Editing by Ted Kerr)